The label-free Octet K2 Biolayer Interferometer is your entry-level system to the automated measurement of molecular interactions at moderate throughput.
Its patented 2-channel design allows you to measure 2 samples in parallel and thus to save time. Quickly and easily characterize protein-protein or protein-small molecule interactions, determine affinity or simply the concentration of active analytes.
The microfluidic-free Dip-and-Read™ format combines the measurement of unpurified mixtures directly in standardized microplates. The flexibility with regards to sample types ranges from molecules sized only 150 Da to viruses or whole human cells.
After measurement, the samples can be used for further processing steps or analyses.
The biosensors can be regenerated and reused when the experiment is over. This reduces your operating costs for consumables.
Increase the efficiency and quality of your research with the Octet K2 Biolayer Interferometer.
Full power across 8 channels: Label-free and GxP-compliant analysis of molecular interactions
Biolayer interferometer system ✓ 8-channel measurement ✓ Active temperature control ✓ Protein-protein interaction assay ✓ Fully automated ✓ GxP compliant ✓ more
Characterize and Quantify Proteins with Only a Single Droplet
Biolayer interferometer system ✓ Minimal space required ✓ Only 4 µL of sample ✓ Protein quantification ✓ Protein kinetics ✓ Protein-protein interactions ✓ more
No need for process delays due to protein analysis: Quantify 96 samples in 2 minutes
Bio-layer interferometer system ✓ High-throughput – 96 biosensors ✓ Protein quantification ✓ Assay for protein-protein interactions ✓ Fully automated ✓ more
Sartorius with continued growth in a challenging environment
Sartorius closed the first nine months of 2022 in both divisions with double-digit sales revenue and earnings growth and specified its outlook for the current fiscal year. “In the first nine months, Sartorius achieved significant growth in a challenging environment. Both divisions recorded ... more
Sartorius records dynamic start to the new fiscal year
Sartorius recorded a dynamic start to fiscal 2022, with sales revenue and earnings posting strong double-digit growth rates in the first quarter compared with the prior-year period. Based on its performance in the first three months, Sartorius confirms its outlook for fiscal 2022. “Sartoriu ... more
Sartorius completes acquisition of Novasep’s chromatography division
Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. T ... more
